The St. Gallen panel, which was made up of 43 of the world’s foremost breast cancer experts from 23 countries5 discussed and voted on a series of treatment recommendations for early breast cancer during an open session on the final day of the St. Gallen International Breast Cancer Conference, held in Vienna in March 2017.
Dr. William Audeh, Chief Medical Officer at Agendia, said: “It is very encouraging to see MammaPrint not only included in these prestigious guidelines for a third time, but to see the MammaPrint recommendation expanded to become one of only two gene-expression tests recommended for making treatment decisions for patients with positive lymph-node involvement.
Ad Statistics
Times Displayed: 50213
Times Visited: 1424 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
“The landmark MINDACT trial provided the highest possible level of clinical evidence to support the clinical utility of MammaPrint, and the St. Gallen Consensus marks the third set of guidelines this year to recommend the test based on this unique data.”
MammaPrint has been recently recognized as being supported by level 1A clinical evidence by the German Gynecological Oncology Group (AGO) in Germany, the European Group on Tumor Markers (EGTM), and is also recommended for use in other important best-practice guidelines including those of the European Society for Medical Oncology (ESMO).
Back to HCB News
